CN118715004A - 含有非索非那定的组合物 - Google Patents

含有非索非那定的组合物 Download PDF

Info

Publication number
CN118715004A
CN118715004A CN202180105441.6A CN202180105441A CN118715004A CN 118715004 A CN118715004 A CN 118715004A CN 202180105441 A CN202180105441 A CN 202180105441A CN 118715004 A CN118715004 A CN 118715004A
Authority
CN
China
Prior art keywords
sodium
spray
aspects
diluent
hydrogen phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180105441.6A
Other languages
English (en)
Chinese (zh)
Inventor
丹妮拉·马尔多纳多·卡瓦拉里
马克西姆·里布雷奥
查基布·扎格卢勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opelle Medical Group
Original Assignee
Opelle Medical Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opelle Medical Group filed Critical Opelle Medical Group
Publication of CN118715004A publication Critical patent/CN118715004A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180105441.6A 2021-12-29 2021-12-29 含有非索非那定的组合物 Pending CN118715004A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/000916 WO2023126637A1 (en) 2021-12-29 2021-12-29 Compositions containing fexofenadine

Publications (1)

Publication Number Publication Date
CN118715004A true CN118715004A (zh) 2024-09-27

Family

ID=80122351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180105441.6A Pending CN118715004A (zh) 2021-12-29 2021-12-29 含有非索非那定的组合物

Country Status (12)

Country Link
US (1) US20250082623A1 (https=)
EP (1) EP4456880B1 (https=)
JP (1) JP7826492B2 (https=)
KR (1) KR20240136358A (https=)
CN (1) CN118715004A (https=)
AR (1) AR128113A1 (https=)
AU (1) AU2021480621A1 (https=)
CA (1) CA3242293A1 (https=)
CO (1) CO2024009774A2 (https=)
MX (1) MX2024008242A (https=)
PE (1) PE20242355A1 (https=)
WO (1) WO2023126637A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
CN102958515A (zh) * 2009-12-02 2013-03-06 阿普塔利斯制药有限公司 非索非那定微胶囊及含有非索非那定微胶囊的组合物
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
CN102512389B (zh) * 2011-12-27 2013-08-21 天津市嵩锐医药科技有限公司 非索非那定盐酸盐口腔崩解药物组合物
KR101761983B1 (ko) * 2014-08-25 2017-08-07 아주대학교산학협력단 구강내 속붕해 필름 조성물 및 그 제조방법
CN105997910A (zh) * 2016-06-09 2016-10-12 北京化工大学 一种掩味制剂及其制备方法

Also Published As

Publication number Publication date
CA3242293A1 (en) 2023-07-06
JP7826492B2 (ja) 2026-03-09
EP4456880B1 (en) 2026-03-18
AU2021480621A1 (en) 2024-07-18
WO2023126637A1 (en) 2023-07-06
PE20242355A1 (es) 2024-12-16
MX2024008242A (es) 2024-07-19
CO2024009774A2 (es) 2024-08-08
US20250082623A1 (en) 2025-03-13
AR128113A1 (es) 2024-03-27
EP4456880A1 (en) 2024-11-06
KR20240136358A (ko) 2024-09-13
JP2024546513A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
JP5837732B2 (ja) ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
ES2951547T3 (es) Composiciones farmacéuticas que comprenden nilotinib
US8048449B2 (en) Mouth dissolving pharmaceutical composition and process for preparing the same
KR101020809B1 (ko) 펙소페나딘을 함유하는 구강 분산성 정제
JP4920798B2 (ja) ２種以上の粒子を含有する口腔内速崩壊錠
TWI398273B (zh) 用於抑制酸分泌之醫藥調配物及其製備及使用之方法
TW200918060A (en) Medical composition containing rebamipide
WO2013125617A1 (ja) １－（３－（２－（１－ベンゾチオフェン－５－イル）エトキシ）プロピル）アゼチジン－３－オールまたはその塩を含有する固形医薬組成物
JP2004175796A (ja) 排尿障害治療用口腔内崩壊製剤
WO2011136751A2 (en) Water soluble pharmaceutical composition
JP2010270110A (ja) ネオテームを含有する経口製剤
KR20100086140A (ko) 몬테루카스트를 활성성분으로 함유하는 구강 내 속붕해정 조성물 및 그 제조방법
CN118715004A (zh) 含有非索非那定的组合物
KR100604034B1 (ko) 암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
JP2003261439A (ja) 口腔内崩壊製剤
JP2007224021A (ja) イグラチモドを含有する速崩壊性錠剤
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
JP2018108950A (ja) レボセチリジン塩酸塩含有口腔内崩壊錠
HK40111138A (zh) 含有非索非那定的组合物
JP2024546513A5 (https=)
WO2019197939A1 (en) Taste masked mouth dissolving formulation of montelukast sodium and levocetirizine hydrochloride
WO2026074306A1 (en) Chewable fexofenadine tablets
CN114364386B (zh) 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
JP2008094751A (ja) プランルカスト水和物含有医薬組成物
KR20160012921A (ko) 블로난세린을 포함하는 구강 속붕해성 제제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111138

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination